targeted therapy

  • August 15, 2020 

    Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted TherapyBookmark

    George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes: 

    A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    Lung cancer at ASCO20 VirtualBookmark

    George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This year’s virtual meeting of the American Society of Clinical Oncology featured presentations on several different targeted therapies that appear to provide improved outcomes for lung cancer patients.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 21, 2018 

    Dana-Farber Researcher Sees Biomarker Potential in ESR1 MutationsBookmark

    Emma Shtivelman, PhD

    Excerpt from OncLive:

    “As a medical oncologist and investigator, Rinath M. Jeselsohn, MD, focuses on the detection and clinical implications of ESR1 mutations in estrogen receptor–positive breast cancer. She is a member of the research team in the lab of Myles A. Brown, MD, at Dana-Farber Cancer Institute in Boston, Massachusetts, where investigators are seeking to elucidate the factors underlying the mechanisms of hormone responsiveness, particularly steroid hormone receptors, in human cancers.

    “Jeselsohn, who has led numerous studies into ESR1 mutations, discussed the field in an interview with OncologyLive®.”

    Go to full article published by OncLive on Aug 3, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 4, 2016 

    Clinical Trial Versus Standard Protocol: Why and How to Enroll in a Trial

    Emma Shtivelman, PhD

    I spend most of my time trying to match cancer patients with clinical trials. I consider this to be the most important service I can provide. I try to find trials that are suitable geographically, have the best treatment rationale, and are likely to accept the patient I am helping based on their personal health and treatment history. In this post, I share some of my thoughts about clinical trial enrollment and why it is so important for patients to consider getting treated through a trial.